According to DRG epidemiology, more than 33 million people in the EU5 suffer from migraines and over 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core treatment…
Prior to the launch of Hemlibra, the hemophilia market consisted solely of factor-based products. The use of factor concentrate is highly varied; brand-dependent dosing and infusion frequencies,…
Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists,…
Copy/Paste the key inputs from the product brochure, per guidance from Solutions. Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the…
Treatment of bladder cancer is influenced by a number of factors including disease stage and histology. The swift entry of immune checkpoint inhibitors has transformed the treatment algorithm for…
Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…
Several new drugs have recently entered the PsA market, including new entries into the biologic disease-modifying antirheumatic drug (bDMARD) and targeted synthetic disease-modifying antirheumatic…
The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/ICSFDCs (i.e., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s…
For the estimated 2.7 million people in the United States who suffer from obsessive-compulsive disorder (OCD), prescription pharmacological therapy involves the use of several approved therapies (e…
Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…
Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…